Here's the hot stuff from Intuitive Surgical $ISRG (+1,22 %)
(NASDAQ: ISRG) Q3 2026 Earnings Release, fresh off the US market close:

🚀 Top-line revenue at a record high

Intuitive Surgical once again posted strong growth in the third quarter of 2026:

• Revenue:
  $3.05 billion → +21.5% YoY
  (Previous year: $2.51 billion)
• Expectations were around $2.91 billion → ISRG significantly beat estimates by over $140 million.
• Instruments & Accessories: The main driver of revenue thanks to extremely high surgery rates.

The key point: ISRG is not only growing through the sale of new robotic systems but is also massively boosting high-margin repeat business (consumables) through rising surgery rates in the installed base.

💰 The cash flow machine continues to scale

The robotics pioneer is also delivering impressive results on the bottom line:

• Non-GAAP EPS:
  $3.00 → +25.0% YoY
  (Previous year: $2.40)
• Expected: $2.65 → A beat of a fantastic +0.35 USD per share!
• Net Income (Non-GAAP):
  $1.05 billion
  (prior year: $867 million)
• Gross Margin: Solid, in the range of ~68.5% – 69%.

And this is where things get really impressive: ISRG breaks the $3 billion in quarterly revenue and converts over 1 billion USD of that directly into net income.

🦾 Procedure Growth = The Real Powerhouse

The most important point in the entire report on MedTech stocks:

Global da Vinci procedure growth = +18% YoY.

This corresponds to:

• A steady double-digit increase in the number of surgeries worldwide.
• Ion System: Continues to be a major growth driver in the lung biopsy segment.

This is the metric I would monitor most closely at Intuitive Surgical—not just system sales.

As long as hospitals use the systems more intensively, high-margin cash flow from instruments and services will automatically follow.

🧨 And now for the forecast: Guidance Upgrade

ISRG is raising the bar for surgery volumes once again for the full year 2026:

• Procedure growth for FY2026: Increased to approx. 14.0% – 15.0% (previously set at a noticeably more conservative level).
• Gross Profit Margin: Expected to remain strong at 68.7% to 69.3%.

The market had previously expressed concerns about a slowdown in hospital investments—ISRG completely dispels these concerns with its financial results.

🧠 da Vinci 5 → The new hardware cycle is getting underway

What’s exciting isn’t just the current business:

The rollout of the new da Vinci 5 (dV5) is gaining momentum at a breakneck pace. The new-generation systems offer significantly higher computing power, AI-powered data analytics, and feedback sensors for surgeons.

This cements ISRG’s global dominance and ensures that existing hospitals quickly upgrade their old da Vinci Xi fleets.

⚠️ But a risk assessment remains essential

The company’s operating performance is excellent.

But that is precisely why the market is scrutinizing its valuation so closely:

• Very high P/E ratio: ISRG has always traded at a massive quality premium (P/E ratio often >50).
• China default risk: A continued subdued consumer and fiscal environment in Asia, as well as attempts by local competitors to challenge the company.
• Budgetary pressure in the healthcare sector: General cost-cutting measures at U.S. hospitals could slow the initial adoption of systems.

⚡💡 The Bottom Line

Intuitive Surgical once again demonstrates who the undisputed king of robotic surgery is.

$3.05 billion in revenue. +21.5%.

$3.00 EPS (vs. $2.65 expected).

$1 billion net income in just one quarter.

18% growth in procedures.

Fundamentals: A top-notch earnings report. Competitive Advantage: Unassailable thanks to patents, software, and lock-in effects.Operating Leverage: Exemplary. Procedural Demand: No signs of weakness whatsoever. Rating: The only fly in the ointment.

Rating for the earnings report: 🟢🔥🔥🔥 “DOUBLE BEAT & PROCEDURE BOOST.”

$ABBN (-0,06 %)
$GE
$RTX (+1,44 %)
$HAL (+0,22 %)
$MMM (+1,83 %)
$NOC (+1,41 %)
$MSCI (+2,03 %)
$ISRG (+1,22 %)
$SPCX (-2,08 %)
$NFLX (+0,2 %)
$DB1 (+0,64 %)
$CME (+0,94 %)
$T (+1,07 %)
$PM (+2,65 %)
$MCO (+2,1 %)
$NEE (+0,52 %)
$UAL (+0,75 %)
$MONC (-1,02 %)
$TXN (+0,4 %)
$META (-0,2 %)
$IBM (+2,16 %)
$SAP (+2,42 %)
$QS (-0,8 %)
$LRCX (-2,49 %)
$TSLA (-1,32 %)
$RMS (+0,5 %)
$NESN (+0,44 %)
$BARC (+1,46 %)
$ROP (+1,53 %)
$DOW (-1,37 %)
$SPOT (+3,01 %)
$NDAQ (+0,32 %)
$AAL (+0,72 %)
$LMT (+2,03 %)
$PG (+0,95 %)
$BX (+2,21 %)
$BESI (-1,38 %)
$VLO (-1,2 %)
$KER (-0,24 %)
$OR (+0,15 %)
$VRSN (-0,56 %)
$WDC (-2,11 %)
$BE (-5,92 %)
$NEM (-2,49 %)
$TOM (+0,08 %)
$AXP (+1,61 %)
$FIX (-5,24 %)

I already bought 15 shares two weeks ago.

Now I'm buying 3 more before the earnings report.

If the results are good, more will follow 🙏

The collaboration with $ISRG (+1,22 %) should give it another boost

$ISRG (+1,22 %) The week went down quite well. One reason could be the online contest by $JNJ (+1,3 %) , which is launching Ottava, a direct competitor, onto the market. Another reason is the slightly lower growth, as the quarterly growth rate has dropped from 14% to 12%.

The following article sums it up quite well:

https://www.tikr.com/de/blog/intuitive-surgical-fell-30-in-2026-as-a-rival-arrived-heres-where-the-stock-could-go

However, the moat and recurring SaaS revenue remain intact. I don’t see a bear case here and remain invested; if the price drops below €300 again, I’ll gladly buy more.

What do you think $ISRG (+1,22 %) ?

Today I sold off $OVH (+4,69 %) and took my profits. Sure, earlier would’ve been better, but oh well.

Thanks to Mr. T, the story about the European solution played out well—that’s what I was betting on. Now it’s time for the business to scale up. I’m keeping an eye on it; if it drops below 10, I’ll definitely buy back in.

I used some of those profits to buy into $NFLX (+0,2 %) and $ISRG (+1,22 %) to add to my positions and expand them. Both are set up so that today’s earnings aren’t the only factor. I also $WINC (-0,29 %) was expanded a bit as well.

After @jkb92 @Raketentoni convinced me to add this intuitive new stock to my portfolio.

Edit: Unfortunately, the link to JKB isn't working for some reason.

Hey community,

I am 24 years old, a student and have been actively investing for almost two years. Like many people, my goal is simply financial freedom and not to depend on the pension system later on

I follow a hybrid strategy: a stable ETF core combined with concentrated individual stocks where I have real conviction. No active trading, but buy and hold, unless I notice that a share is getting hot, then I sell and buy again at a lower price when it has corrected.

My underlying strategy:

in the first few years, I blindly followed many trends and other "finfluencers" and didn't always make good and wise decisions as a result. When I invest in individual stocks now, I do so with conviction and that they are future-oriented and will bring me long-term returns.

I would like to reduce the USA share to ~55% in the medium term

I have around €2,500 in cash that I would like to invest now. On my watchlist: $ISRG (+1,22 %) Intuitive Surgical , $ACN (+4,49 %) Accenture, Space X and $POET (-10,6 %) Poet Technologies $AXTI (-14,38 %)

I know it's not an exciting portfolio rather basic but maybe I would like to change that :)

I am grateful for any honest feedback, even if it is uncomfortable.